Abstract:Background Alzheimer's disease (AD) is characterized by progressive deterioration of cognitive functions. Some individuals with subjective cognitive decline (SCD) are in the early phase of the disease and subsequently progress through the AD continuum. Although neuroimaging biomarkers could be used for the accurate and early diagnosis of preclinical AD, the findings in SCD samples have been heterogeneous. This study established the morphological differences in brain magnetic resonance imaging (MRI) findings between individuals with SCD and those without cognitive impairment based on a clinical sample of patients defined according to SCD-Initiative recommendations. Moreover, we investigated baseline structural changes in the brains of participants who remained stable or progressed to mild cognitive impairment or dementia. Methods This study included 309 participants with SCD and 43 healthy controls (HCs) with high-quality brain MRI at baseline. Among the 99 subjects in the SCD group who were followed clinically, 32 progressed (SCDp) and 67 remained stable (SCDnp). A voxel-wise statistical comparison of gray and white matter (WM) volume was performed between the HC and SCD groups and between the HC, SCDp, and SCDnp groups. XTRACT ATLAS was used to define the anatomical location of WM tract damage. Region-of-interest (ROI) analyses were performed to determine brain volumetric differences. White matter lesion (WML) burden was established in each group. Results Voxel-based morphometry (VBM) analysis revealed that the SCD group exhibited gray matter atrophy in the middle frontal gyri, superior orbital gyri, superior frontal gyri, right rectal gyrus, whole occipital lobule, and both thalami and precunei. Meanwhile, ROI analysis revealed decreased volume in the left rectal gyrus, bilateral medial orbital gyri, middle frontal gyri, superior frontal gyri, calcarine fissure, and left thalamus. The SCDp group exhibited greater hippocampal atrophy ( p < 0.001) than the SCDnp and HC groups on ROI analyses. On VBM analysis, however, the SCDp group exhibited increased hippocampal atrophy only when compared to the SCDnp group ( p < 0.001). The SCD group demonstrated lower WM volume in the uncinate fasciculus, cingulum, inferior fronto-occipital fasciculus, anterior thalamic radiation, and callosum forceps than the HC group. However, no significant differences in WML number ( p = 0.345) or volume ( p = 0.156) were observed between the SCD and HC groups. Conclusions The SCD group showed brain atrophy mainly in the frontal and occipital lobes. However, only the SCDp group demonstrated atrophy in the medial temporal lobe at baseline. Structural damage in the brain regions was anatomically connected, which may contribute to early memory decline.

Biomarkers of Alzheimer’s disease and cerebrovascular disease in relation to depressive symptomatology in individuals with subjective cognitive decline

Depressive Symptoms Are Not Associated with Predementia Cerebrospinal Fluid Amyloid Pathology

Differential neuropsychiatric associations of plasma biomarkers in older adults with major depression and subjective cognitive decline

The association between AD biomarkers and neuropsychiatric symptoms in subjective cognitive decline; the SCIENCe project

Changes in Multiparametric Magnetic Resonance Imaging and Plasma Amyloid-Beta Protein in Subjective Cognitive Decline

Aberrant functional connectivity network in subjective memory complaint individuals relates to pathological biomarkers

Association of Subjective Cognitive Decline with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: the CABLE Study.

Dyadic patterns of subjective cognitive decline relate to Alzheimer’s disease biomarkers differently in preclinical and prodromal clinical states

Cognitive status and demographics modify the association between subjective cognition and amyloid

Cerebral Amyloidosis in Individuals with Subjective Cognitive Decline: From Genetic Predisposition to Actual Cerebrospinal Fluid Measurements

Altered Functional Connectivity Pattern of Hippocampal Subfields in Individuals with Objectively-Defined Subtle Cognitive Decline and Its Association with Cognition and Cerebrospinal Fluid Biomarkers

Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer's disease

Structural neuroimaging changes associated with subjective cognitive decline from a clinical sample

Longitudinal assessment of plasma biomarkers for early detection of cognitive changes in subjective cognitive decline

Subtle executive deficits are associated with higher brain amyloid burden and lower cortical volume in subjective cognitive decline: the FACEHBI cohort

Sex and Education Modify the Association Between Subjective Cognitive Decline and Amyloid Pathology

Awareness of episodic memory and meta-cognitive profiles: associations with cerebrospinal fluid biomarkers at the preclinical stage of the Alzheimer's continuum

18F-AV45 PET and MRI Reveal the Influencing Factors of Alzheimer's Disease Biomarkers in Subjective Cognitive Decline Population.

Neuroanatomical and neurocognitive changes associated with subjective cognitive decline

Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers

Brain Functional Alterations and Association with Cognition in People with Preclinical Subjective Cognitive Decline and Objective Subtle Cognitive Difficulties.